VIDEO: ‘Exciting time’ for development of oral selective estrogen degraders

In this video, Sara Hurvitz, MD, discussed recent developments in oral selective estrogen degraders reviewed at 39th Miami Breast Cancer Conference.
"It's a really exciting time right now with data just emerging relating to how the oral [selective estrogen degraders (SERDs)] work compared to standard of endocrine therapy," said Hurvitz, an associate professor at David Geffen School of Medicine at UCLA and medical director of Jonsson Comprehensive Cancer Center Clinical Research Unit.
Results from the EMERALD trial, a multicenter, international, randomized, open-label, controlled phase 3 trial

In this video, Sara Hurvitz, MD, discussed recent developments in oral selective estrogen degraders reviewed at 39th Miami Breast Cancer Conference.
«It’s a really exciting time right now with data just emerging relating to how the oral [selective estrogen degraders (SERDs)] work compared to standard of endocrine therapy,» said Hurvitz, an associate professor at David Geffen School of Medicine at UCLA and medical director of Jonsson Comprehensive Cancer Center Clinical Research Unit.
Results from the EMERALD trial, a multicenter, international, randomized, open-label, controlled phase 3 trial